Sarah Rybowski - Concepedia

Author

Sarah Rybowski

Eli Lilly (United States)

Also Known As

Rybowski, Sarah, S. Rybowski, Sarah Rybowski

Publications

467

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Bayer (Germany)Bayer (United States)Memorial Sloan Kettering Cancer Center Väestöliitto

About

Sarah Rybowski is an author at Eli Lilly (United States) specializing in maternal health, obstetrics, and reproductive health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	61
2	Public Health	1	1	61
3	Obstetrics	1	1	61
4	Reproductive Health	1	1	61
5	Fertility	1	1	61

Sarah Rybowski

Publications

413

Citations

H-Index

Page 1

	Year	Citations
Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems Anita L. Nelson, Dan Apter, Brian Hauck, Obstetrics and Gynecology	2013	153
The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial Kristina Gemzell‐Danielsson, Dan Apter, Brian Hauck, PLoS ONE	2015	62
A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant Dan Apter, Paula Briggs, Marjo Tuppurainen, Fertility and Sterility Hormonal ContraceptiveLevonorgestrel Intrauterine SystemFertilityReproductive HealthEtonogestrel Subdermal Implant	2016	61
Women's attitudes towards monthly bleeding: Results of a global population-based survey Anne Szarewski, Ariane von Stenglin, Sarah Rybowski The European Journal of Contraception & Reproductive Health Care	2012	45
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2− metastatic breast cancer Gebra Cuyún Carter, Kristin M. Sheffield, Anala Gossai, Current Medical Research and Opinion	2021	36
Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting Gregory L. Price, Lavanya Sudharshan, Paula D. Ryan, Current Medical Research and Opinion	2022	17
A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age Lynn Borgatta, Kai J. Bühling, Sarah Rybowski, The European Journal of Contraception & Reproductive Health Care	2016	16
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib Emily Nash Smyth, Julie Beyrer, Kimberly R. Saverno, Drugs - Real World Outcomes	2022	13
Abstract P2-08-12: Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2- metastatic breast cancer Gebra Cuyún Carter, Kristin M. Sheffield, Anala Gossai, Cancer Research	2020	10

Page 1